IART Stock Recent News

Integra's (IART) strong focus on portfolio optimization and international expansion bolsters investors' confidence in the stock.

Integra (IART) reported earnings 30 days ago. What's next for the stock?

Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.

Integra's (IART) Q4 revenues are impacted by the decline in the Tissue Technologies segment.

The headline numbers for Integra (IART) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Integra LifeSciences (IART) came out with quarterly earnings of $0.89 per share, missing the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $0.94 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Integra (IART), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.